{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.94, "exchange": "STU", "shortName": "Clearside Biomedical Inc.", "longName": "Clearside Biomedical, Inc.", "messageBoardId": "finmb_145617165", "exchangeTimezoneName": "Europe/Berlin", "market": "dr_market", "regularMarketTime": 1683905168, "regularMarketDayHigh": 0.975, "regularMarketDayRange": "0.94 - 0.975", "regularMarketDayLow": 0.94, "regularMarketVolume": 0, "regularMarketPreviousClose": 0.94, "bid": 0.955, "ask": 1.03, "bidSize": 0, "askSize": 0, "fullExchangeName": "Stuttgart", "financialCurrency": "USD", "regularMarketOpen": 0.975, "averageDailyVolume3Month": 559, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.11500001, "fiftyTwoWeekLowChangePercent": 0.13939396, "fiftyTwoWeekRange": "0.825 - 1.7465", "fiftyTwoWeekHighChange": -0.8065, "fiftyTwoWeekHighChangePercent": -0.4617807, "fiftyTwoWeekLow": 0.825, "fiftyTwoWeekHigh": 1.7465, "earningsTimestamp": 1683808200, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.5, "epsForward": -0.39, "epsCurrentYear": -0.15, "priceEpsCurrentYear": -6.2666664, "sharesOutstanding": 61666100, "bookValue": 0.175, "fiftyDayAverage": 0.985758, "fiftyDayAverageChange": -0.04575801, "fiftyDayAverageChangePercent": -0.04641911, "twoHundredDayAverage": 1.1807865, "twoHundredDayAverageChange": -0.2407865, "twoHundredDayAverageChangePercent": -0.20392044, "marketCap": 57966132, "forwardPE": -2.4102564, "priceToBook": 5.3714285, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1520578800000, "priceHint": 4, "regularMarketChange": 0.0, "symbol": "CLM.SG"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "900 North Point Parkway", "address2": "Suite 200", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "(678) 270-3631", "fax": "(678) 270-4033", "website": "https://clearsidebio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.", "age": 70, "title": "Pres, CEO & Director", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": {"raw": 816400, "fmt": "816.4k", "longFmt": "816,400"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Charles A. Deignan", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 536950, "fmt": "536.95k", "longFmt": "536,950"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 24545, "fmt": "24.55k", "longFmt": "24,545"}}, {"maxAge": 1, "name": "Dr. Thomas A. Ciulla M.B.A., M.D.", "age": 57, "title": "Chief Medical Advisor-Retina", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 597205, "fmt": "597.21k", "longFmt": "597,205"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jenny R. Kobin", "age": 55, "title": "Head of Investor Relations", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rick  McElheny", "title": "VP of Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rafael V. Andino", "age": 57, "title": "Sr. VP of Engineering & Manufacturing", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Susan L. Coultas Ph.D.", "title": "Chief Clinical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Leslie B. Zacks", "age": 53, "title": "Sec.", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}